Generic Name:
ibrutinib
Project Status:
Pending
Therapeutic Area:
Chronic lymphocytic leukemia (CLL)
Manufacturer:
Janssen Inc.
Call for patient/clinician input open:
Brand Name:
Imbruvica
Project Line:
Reimbursement Review
Project Number:
PC0317-000
Call for patient/clinician input closed:
Tumour Type:
Leukemia
Details
Manufacturer Requested Reimbursement Criteria1:
Imbruvica with venetoclax for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL), including those with 17p deletion.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Imbruvica with venetoclax for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL), including those with 17p deletion.
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.